mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Kathryn E. O'Reilly, Fredi Rojo, Qing Bai She, David Solit, Gordon Mills, Debra Smith, Heidi Lane, Francesco Hofmann, Daniel J. Hicklin, Dale L. Ludwig, Jose Baselga, Neal Rosen

Research output: Contribution to journalArticle

1891 Citations (Scopus)

Abstract

Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway. In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin. Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity. We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin derivative, RAD001. IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR. In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium. The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation. Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.

Original languageEnglish (US)
Pages (from-to)1500-1508
Number of pages9
JournalCancer Research
Volume66
Issue number3
DOIs
StatePublished - Feb 1 2006
Externally publishedYes

Fingerprint

Receptor Protein-Tyrosine Kinases
Sirolimus
Insulin Receptor Substrate Proteins
Neoplasms
IGF Type 1 Receptor
1-Phosphatidylinositol 4-Kinase
Down-Regulation
Serum-Free Culture Media
Therapeutic Uses
Insulin-Like Growth Factor I
Phosphotransferases
Insulin
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

O'Reilly, K. E., Rojo, F., She, Q. B., Solit, D., Mills, G., Smith, D., ... Rosen, N. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research, 66(3), 1500-1508. https://doi.org/10.1158/0008-5472.CAN-05-2925

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. / O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing Bai; Solit, David; Mills, Gordon; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal.

In: Cancer Research, Vol. 66, No. 3, 01.02.2006, p. 1500-1508.

Research output: Contribution to journalArticle

O'Reilly, KE, Rojo, F, She, QB, Solit, D, Mills, G, Smith, D, Lane, H, Hofmann, F, Hicklin, DJ, Ludwig, DL, Baselga, J & Rosen, N 2006, 'mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt', Cancer Research, vol. 66, no. 3, pp. 1500-1508. https://doi.org/10.1158/0008-5472.CAN-05-2925
O'Reilly, Kathryn E. ; Rojo, Fredi ; She, Qing Bai ; Solit, David ; Mills, Gordon ; Smith, Debra ; Lane, Heidi ; Hofmann, Francesco ; Hicklin, Daniel J. ; Ludwig, Dale L. ; Baselga, Jose ; Rosen, Neal. / mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. In: Cancer Research. 2006 ; Vol. 66, No. 3. pp. 1500-1508.
@article{be254592ce434d8fbac47b1a289c833f,
title = "mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt",
abstract = "Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway. In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin. Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity. We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin derivative, RAD001. IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR. In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium. The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation. Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.",
author = "O'Reilly, {Kathryn E.} and Fredi Rojo and She, {Qing Bai} and David Solit and Gordon Mills and Debra Smith and Heidi Lane and Francesco Hofmann and Hicklin, {Daniel J.} and Ludwig, {Dale L.} and Jose Baselga and Neal Rosen",
year = "2006",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-05-2925",
language = "English (US)",
volume = "66",
pages = "1500--1508",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

AU - O'Reilly, Kathryn E.

AU - Rojo, Fredi

AU - She, Qing Bai

AU - Solit, David

AU - Mills, Gordon

AU - Smith, Debra

AU - Lane, Heidi

AU - Hofmann, Francesco

AU - Hicklin, Daniel J.

AU - Ludwig, Dale L.

AU - Baselga, Jose

AU - Rosen, Neal

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway. In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin. Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity. We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin derivative, RAD001. IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR. In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium. The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation. Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.

AB - Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway. In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin. Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity. We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin derivative, RAD001. IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR. In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium. The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation. Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.

UR - http://www.scopus.com/inward/record.url?scp=32944457518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944457518&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-2925

DO - 10.1158/0008-5472.CAN-05-2925

M3 - Article

C2 - 16452206

AN - SCOPUS:32944457518

VL - 66

SP - 1500

EP - 1508

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -